Loading clinical trials...

Novel Neuroimage Study in Tauopathies With Parkinsonism | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Novel Neuroimage Study in Tauopathies With Parkinsonism

NCT03386669•Chang Gung Memorial Hospital

Summary

The aims of this study are: 18F-THK5351 PET(Positron Emission Tomography) can defect the tau burden in PSP(Progressive Supranuclear Palsy) and CBS (Corticobasal syndrome)correlating with the known NFT(neurofibrillary tangles) topology of those diseases, 18F-THK5351 PET will differentiate subjects with suspected tauopathy due to PSP and CBS from subjects with suspected synucleinopathy due to idiopathic PD(Parkinson's disease). The distribution of PHF(paired helical filament) tau burden will correlate with specific motor and cognitive features of PSP and CBS; and regional PHF tau burden will be associated with cortical thinning. Together, these efforts will establish the potential for developing 18F-THK5351 PET imaging as a biomarker and diagnostic tool for the parkinsonian tauopathies.

Eligibility

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. 20 subjects with a diagnosis of PD whom must:
•* Age ranges from 20-80 years
•* Patients should be fulfilled "UK(United Kingdom ) Parkinson's Disease Society Brain Bank Criteria for the diagnosis of PD", 2.11.1 Appendix I, (27)
•* Patients who provide a written informed consent prior to study entry. If the patient is incapable of informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm assent).
•2. 20 subjects with a diagnosis of PSP whom must:
•* Age ranges from 20-80 years
•* Patients fulfill the criteria of NINDS-SPSP(National Institute of Neurological Disorders and Stroke / Society for PSP) clinical criteria for the diagnosis of PSP "as possible" or "probably" PSP, 2.11.2 Appendix II, (28)
•* Patients who provide a written informed consent prior to study entry. If the patient is incapable of informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm assent).
•3. 20 subjects with a diagnosis of CBS whom must:
•* Age ranges from 20-80 years
+2 more criteria

Exclusion Criteria

•1. Implantation of metal devices including cardiac pacemaker, intravascular metal devices.
•2. Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases
•3. Major psychiatric disorders, drug or alcohol abuse and major depression
•4. Pregnant women or breast- feeding women
•5. Patients in whom MRI was contraindicated
•6. History of severe allergic or anaphylactic reactions particularly to the tested drugs
•7. Indication of impaired liver function as shown by an abnormal liver function profile at screening (eg. repeated values of aspartate aminotransferase \[AST(aspartate aminotransferase)\] and alanine aminotransferase \[ALT(Alanine aminotransferase)\] ≧ 3X(3 Times) the upper limit of normal values)

Locations (1)

Chang Gung Memorial Hospital,Linkou

Taoyuan, Guishan Dist, Taiwan

Key Dates

Start Date

July 31, 2017

Primary Completion Date

July 31, 2019

Completion Date

July 31, 2019

Last Updated

January 27, 2021

Enrollment

ACTUAL participants

Conditions

Parkinsonism

Interventions

F-18

DRUG

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients

NCT07442370

Parkinson DiseaseParkinsonism

View study

RECRUITINGNA

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

NCT07056361

Movement Disorders (Incl Parkinsonism)Stroke+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Novel Neuroimage Study in Tauopathies With Parkinsonism

Inclusion Criteria

Exclusion Criteria

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.

Aim 3 Particle Swarm Optimization PIGD

Proteinopathies Expression in Skin of Neurodegenerative Disorders

The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders